Setrusumab
Phase 2/3Active 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteogenesis Imperfecta
Conditions
Osteogenesis Imperfecta
Trial Timeline
Feb 21, 2022 → Apr 1, 2027
NCT ID
NCT05125809About Setrusumab
Setrusumab is a phase 2/3 stage product being developed by Ultragenyx Pharmaceutical for Osteogenesis Imperfecta. The current trial status is active. This product is registered under clinical trial identifier NCT05125809. Target conditions include Osteogenesis Imperfecta.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06636071 | Phase 3 | Active |
| NCT05312697 | Phase 2 | Terminated |
| NCT05125809 | Phase 2/3 | Active |
Competing Products
16 competing products in Osteogenesis Imperfecta
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide (FORTEO) + Placebos | Eli Lilly | Approved | 85 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 3 | 77 |
| Romosozumab + Bisphosphonate | Amgen | Phase 3 | 76 |
| Romosozumab | Amgen | Phase 1 | 32 |
| Denosumab | Amgen | Phase 3 | 76 |
| Denosumab + Alternative osteoporosis medications | Amgen | Phase 3 | 76 |
| Fresolimumab | Sanofi | Phase 1 | 32 |
| SAR439459 + Placebo | Sanofi | Phase 1 | 32 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| setrusumab + zoledronic acid (optional) | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Bisphosphonate + Setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |